ArticleJournal of clinical gastroenterology2016
Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection.
Article in Journal of clinical gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03724175 (The Role of Secondary Bile Acids in Intestinal Inflammation), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Secondary Bile Acids in Intestinal Inflammation
Who cites it
63 citing papers in PubMed, 134 citations in OpenAlex.
- The gut microbiome-bile acid-FXR interplay: a pivotal axis in metabolic and gastrointestinal diseases.Gut microbes · 2026Review
- Review
- Cryptosporidium parvum multidrug resistance protein confers resistance to toxic gut microbial metabolite.Cell host & microbe · 2025Article
- Pterostilbene attenuates intestinal barrier damage and secondary liver oxidative stress in a murine model ofFood & function · 2025Article
- Gut microbiota in the development and progression of chronic liver diseases: Gut microbiota-liver axis.World journal of hepatology · 2025Review
- How bile acids and the microbiota interact to shape host immunity.Nature reviews. Immunology · 2024Review
- Article
- Altered Bile Acid and Pouch Microbiota Composition in Patients With Chronic Pouchitis.Inflammatory bowel diseases · 2024Article
- Current and Ongoing Developments in TargetingMicroorganisms · 2024Review
- Determination of Bile Acids in Canine Biological Samples: Diagnostic Significance.Metabolites · 2024Review
- The design, synthesis, and inhibition of Clostridioides difficile spore germination by acyclic and bicyclic tertiary amide analogs of cholate.European journal of medicinal chemistry · 2023Article
- Returning to Nature for the Next Generation of Antimicrobial Therapeutics.Antibiotics (Basel, Switzerland) · 2023Review
- Mechanism of germination inhibition of Clostridioides difficile spores by an aniline substituted cholate derivative (CaPA).The Journal of antibiotics · 2023Article
- Gut Microbial Metabolites on Host Immune Responses in Health and Disease.Immune network · 2023Review
- Epigallocatechin-3-Gallate Improves Intestinal Gut Microbiota Homeostasis and AmelioratesNutrients · 2022Article
- Identification and Characterization of Major Bile Acid 7α-Dehydroxylating Bacteria in the Human Gut.mSystems · 2022Article
- Capturing the environment of the Clostridioides difficile infection cycle.Nature reviews. Gastroenterology & hepatology · 2022Review
- Article
- The Role of Bile Acids in the Human Body and in the Development of Diseases.Molecules (Basel, Switzerland) · 2022Review
- Bile acid detergency: permeability, inflammation, and effects of sulfation.American journal of physiology. Gastrointestinal and liver physiology · 2022Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
goalsTo test whether ursodeoxycholic acid (UDCA) is inhibitory to Clostridium difficile and can be used in the treatment of C. difficile-associated ileal pouchitis.
backgroundThe restoration of secondary bile metabolism may be the key mechanism for fecal microbiota transplantation (FMT) in treating recurrent C. difficile infections (RCDI). Therefore, it is possible that exogenous administration of inhibitory bile acids may be used directly as nonantibiotic therapeutics for this indication. The need for such a treatment alternative is especially significant in patients with refractory C. difficile-associated pouchitis, where the efficacy of FMT may be limited. STUDY: We measured the ability of UDCA to suppress the germination and the vegetative growth of 11 clinical isolate strains of C. difficile from patients treated with FMT for RCDI. In addition, we used oral UDCA to treat a patient with RCDI pouchitis that proved refractory to multiple antibiotic treatments and FMT.
resultsUDCA was found to be inhibitory to the germination and the vegetative growth of all C. difficile strains tested. Fecal concentrations of UDCA from the patient with RCDI pouchitis exceeded levels necessary to inhibit the germination and the growth of C. difficile in vitro. The patient has remained infection free for over 10 months after the initiation of UDCA.
conclusionsUDCA can be considered as a therapeutic option in patients with C. difficile-associated pouchitis. Further studies need to be conducted to define the optimal dose and duration of such a treatment. In addition, bile acid derivatives inhibitory to C. difficile that are able to achieve high intracolonic concentrations may be developed as therapeutics for RCDI colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.